RxDoctor Payments Data

Annalyse Quintero, MD

Family Medicine · Puyallup, WANPI 1760917363

Payments from drug & device makers

$624in general payments, 2019–2025

Across 12 payments — averaging $51.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$167
  • GSK$145
  • Bayer$125
  • Novo Nordisk$111
  • Organon$49
  • Sanofi Pasteur Inc.$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$167
GSK2$145
Bayer1$125
Novo Nordisk2$111
Organon3$49
Sanofi Pasteur Inc.1$14
Pfizer1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624 in reported general payments places this provider in the 80th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$84,003
Medicare patients
273
Services billed
2,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$56,030
EliquisApixaban33$53,638
TrulicityDulaglutide34$49,215
OzempicSemaglutide29$46,146
XareltoRivaroxaban32$42,974
TradjentaLinagliptin44$34,302
JanuviaSitagliptin Phosphate21$27,393
MounjaroTirzepatide15$19,584
Spiriva RespimatTiotropium Bromide19$17,700
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,512
KerendiaFinerenone14$12,486
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$11,537
Spiriva HandihalerTiotropium Bromide20$11,506
EntrestoSacubitril/Valsartan12$8,005
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$53,63833 claims
Novo NordiskOzempic$111$46,14629 claims
GSKTrelegy Ellipta, Arnuity Ellipta$145$21,35928 claims
BayerKerendia$125$12,48614 claims
AstraZenecaSymbicort$167$4,86319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Puyallup

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →